Nef-M1, a CXCR4 Peptide Antagonist, Enhances Apoptosis and Inhibits Primary Tumor Growth and Metastasis in Breast Cancer

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journal of Cancer Therapy

ISSN Print: 2151-1934
ISSN Online: 2151-1942
www.scirp.org/journal/jct
E-mail: jct@scirp.org

Citations h5-index & Ranking

Journals Menu

"Nef-M1, a CXCR4 Peptide Antagonist, Enhances Apoptosis and Inhibits Primary Tumor Growth and Metastasis in Breast Cancer"
written by Harvey Bumpers, Ming-Bo Huang, Venkat Katkoori, Upender Manne, Vincent Bond,
published by Journal of Cancer Therapy, Vol.4 No.4, 2013

has been cited by the following article(s):

Google Scholar
CrossRef

[1]	CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple …
	Cancer Letters, 2022

[2]	Peptide therapeutics in the management of metastatic cancers
	RSC advances, 2022

[3]	Peptide-Based Molecular Constructs for Cellular Targeting and Small Molecule Delivery
	2020

[4]	Emerging Peptide-Based Technologies in Cancer Therapy
	2019

[5]	趋化因子受体 4/趋化因子配体 12 轴与胃癌发生发展关系研究进展
	中国药理学与毒理学 …, 2019

[6]	Endothelial Selectin-targeted Nanoparticles for Enhancing Drug Delivery to Solid Tumors
	2018

[7]	Quinic Acid‐Conjugated Nanoparticles Enhance Drug Delivery to Solid Tumors via Interactions with Endothelial Selectins
	Small, 2018

[8]	Targeted Theranostic Nanoparticles for Brain Tumor Treatment
	Pharmaceutics, 2018

[9]	GPCR Modulation in Breast Cancer
	2018

[10]	Head injuries in urban environment skiing and snowboarding: a retrospective study on injury severity and injury mechanisms
	2018

[11]	Small molecule CXCR4 antagonists block the HIV-1 Nef/CXCR4 axis and selectively initiate the apoptotic program in breast cancer cells
	Oncotarget, 2018

[12]	Seek & Destroy, use of targeting peptides for cancer detection and drug delivery
	Bioorganic & Medicinal Chemistry, 2017

[13]	Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma
	Cancer medicine, 2017

[14]	Secretion modification region-derived peptide blocks exosome release and mediates cell cycle arrest in breast cancer cells
	Oncotarget, 2017

[15]	CXCR4/CXCL12 介导乳腺癌转移的相关机制及治疗进展
	医学综述, 2016

[16]	CXCR4 and CCR7: Two eligible targets in targeted cancer therapy
	Cell biology international, 2016

[17]	CXCR4 Biomarker Expression in Invasive Ductal Carcinoma of the Breast and Its Relation with Axillary Lymph Node Metastasis.
	International Journal of Health Sciences and Research (IJHSR), 2016

[18]	Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs
	Scientific reports, 2016

[19]	CXCR4 Biomarker Expression in Invasive Ductal Carcinoma of the Breast and Its Relation with Axillary Lymph Node Metastasis
	2016

[20]	Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial-to-mesenchymal transition in colon and breast cancers
	Oncotarget, 2015

[1]	Peptide therapeutics in the management of metastatic cancers RSC Advances, 2022 DOI:10.1039/D2RA02062A

[2]	CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer Cancer Letters, 2022 DOI:10.1016/j.canlet.2022.215944

[3]	Unravelling Cancer Signaling Pathways: A Multidisciplinary Approach 2019 DOI:10.1007/978-981-32-9816-3_2

[4]	Small molecule CXCR4 antagonists block the HIV-1 Nef/CXCR4 axis and selectively initiate the apoptotic program in breast cancer cells Oncotarget, 2018 DOI:10.18632/oncotarget.24580

[5]	Quinic Acid-Conjugated Nanoparticles Enhance Drug Delivery to Solid Tumors via Interactions with Endothelial Selectins Small, 2018 DOI:10.1002/smll.201803601

[6]	GPCR Modulation in Breast Cancer International Journal of Molecular Sciences, 2018 DOI:10.3390/ijms19123840

[7]	Quinic Acid‐Conjugated Nanoparticles Enhance Drug Delivery to Solid Tumors via Interactions with Endothelial Selectins Small, 2018 DOI:10.1002/smll.201803601

[8]	Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma Cancer Medicine, 2017 DOI:10.1002/cam4.1085

[9]	Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma Cancer Medicine, 2017 DOI:10.1002/cam4.1085

[10]	Seek & Destroy , use of targeting peptides for cancer detection and drug delivery Bioorganic & Medicinal Chemistry, 2017 DOI:10.1016/j.bmc.2017.08.052

[11]	CXCR4 and CCR7: Two eligible targets in targeted cancer therapy Cell Biology International, 2016 DOI:10.1002/cbin.10631

[12]	Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs Scientific Reports, 2016 DOI:10.1038/srep35765

[13]	CXCR4 and CCR7: Two eligible targets in targeted cancer therapy Cell Biology International, 2016 DOI:10.1002/cbin.10631

[14]	Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs Scientific Reports, 2016 DOI:10.1038/srep35765

[15]	Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial-to-mesenchymal transition in colon and breast cancers Oncotarget, 2015 DOI:10.18632/oncotarget.4615

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journal of Cancer Therapy

Journal of Cancer Therapy

Journals Menu

Home

About SCIRP

Service

Policies